ZNF217 and breast cancer: The most remarkable results arose from analysis of publicly available microarray data for 2,414 and 2,978 breast cancer patients [77, 78], in which it was found that high levels of expression of ZNF217 were associated with poor prognosis, with p values of, respectively, 1 × 10−11 [20] and 3 × 10−9 [51].